Login / Signup

The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohort.

Maria Consiglia FerrieroFrancesco PrataRiccardo MastroianniCosimo De NunzioGiorgia TemaGabriele TudertiAlfredo Maria BoveUmberto AnceschiAldo BrassettiLeonardo MisuracaSilvana GiacintiFabio CalabròSalvatore GuaglianoneAndrea TubaroRocco PapaliaCostantino LeonardoMichele GallucciGiuseppe Simone
Published in: Prostate cancer and prostatic diseases (2022)
Low-volume mCRPC patients are exposed to improved PFS and seem to benefit from locoregional treatments.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • small cell lung cancer
  • squamous cell carcinoma
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • clinical trial
  • patient reported outcomes